I期临床试验-话题@MedSci

#I期临床试验#

226篇内容 | 3901人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2088744, encodeId=f9172088e44f8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, objectType=article, longId=165920, objectId=671e16592080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=671e16592080, replyNumber=0, likeNumber=106, createdTime=2020-02-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=671e16592080, moduleTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=671e16592080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088757, encodeId=e6b12088e5788, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, objectType=article, longId=176549, objectId=9a1f1e654908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1f1e654908, replyNumber=0, likeNumber=147, createdTime=2019-09-20, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1f1e654908, moduleTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1f1e654908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088734, encodeId=65c32088e348d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=基石药业HDAC6抑制剂CS3003在中国I期临床试验获批, objectType=article, longId=162295, objectId=862416229577, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=862416229577, replyNumber=0, likeNumber=70, createdTime=2019-12-12, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=862416229577, moduleTitle=基石药业HDAC6抑制剂CS3003在中国I期临床试验获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=862416229577)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088728, encodeId=664a2088e2831, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=104, createdTime=2019-04-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088724, encodeId=1ad42088e24ad, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=70, createdTime=2020-02-01, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088742, encodeId=38582088e42f1, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=58, createdTime=2019-10-18, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088762, encodeId=52ea2088e6266, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, objectType=article, longId=178054, objectId=7b581e8054f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b581e8054f4, replyNumber=0, likeNumber=72, createdTime=2019-08-25, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b581e8054f4, moduleTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b581e8054f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088758, encodeId=7f752088e586c, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=72, createdTime=2020-02-13, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088763, encodeId=fa822088e63a2, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=Chi-Med在中国启动HMPL-523治疗免疫性血小板减少症（ITP）的I期临床试验, objectType=article, longId=178212, objectId=d4f41e82121f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4f41e82121f, replyNumber=0, likeNumber=50, createdTime=2020-02-06, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4f41e82121f, moduleTitle=Chi-Med在中国启动HMPL-523治疗免疫性血小板减少症（ITP）的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4f41e82121f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088754, encodeId=b6a12088e549d, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=65, createdTime=2019-07-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088759, encodeId=73b12088e59b5, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=60, createdTime=2020-06-07, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088733, encodeId=af462088e3326, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, objectType=article, longId=161551, objectId=9ed316155121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed316155121, replyNumber=0, likeNumber=69, createdTime=2019-04-20, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed316155121, moduleTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed316155121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088747, encodeId=f1e52088e4744, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, objectType=article, longId=168391, objectId=bfb4168391a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfb4168391a4, replyNumber=0, likeNumber=65, createdTime=2019-12-30, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfb4168391a4, moduleTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfb4168391a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088708, encodeId=f0ae2088e084e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=70, createdTime=2019-05-15, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088743, encodeId=ab642088e4306, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, objectType=article, longId=165917, objectId=84ae16591e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ae16591e2f, replyNumber=0, likeNumber=66, createdTime=2020-01-05, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ae16591e2f, moduleTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ae16591e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088713, encodeId=e0112088e1329, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156414, objectId=bb9a156414cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9a156414cc, replyNumber=0, likeNumber=49, createdTime=2019-04-16, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9a156414cc, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9a156414cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088752, encodeId=9f722088e5240, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, objectType=article, longId=174342, objectId=3d2b1e4342ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d2b1e4342ca, replyNumber=0, likeNumber=67, createdTime=2019-08-20, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d2b1e4342ca, moduleTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d2b1e4342ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088731, encodeId=3f632088e3159, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=57, createdTime=2019-06-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088727, encodeId=01702088e276a, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, objectType=article, longId=160532, objectId=d280160532df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d280160532df, replyNumber=0, likeNumber=56, createdTime=2019-08-16, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d280160532df, moduleTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d280160532df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2088706, encodeId=0b3d2088e061e, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=76, createdTime=2019-04-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床试验

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性

2020-02-10

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点

2019-09-20

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

基石药业HDAC6抑制剂CS3003在中国I期临床试验获批

2019-12-12

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-04-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2020-02-01

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2019-10-18

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始

2019-08-25

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2020-02-13

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

Chi-Med在中国启动HMPL-523治疗免疫性血小板减少症（ITP）的I期临床试验

2020-02-06

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2019-07-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2020-06-07

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果

2019-04-20

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者

2019-12-30

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2019-05-15

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血

2020-01-05

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2019-04-16

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症

2019-08-20

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-06-28

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

FDA批准新型心血管支持液VBI-1进入II期临床试验

2019-08-16

839640778 (审核中...)

前往app查看评论内容

#I期临床试验#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2019-04-28

科室
- - 订阅+
  - 更多科室
工具
服务